CY1116802T1 - Ετεροκυκλικες ενωσεις - Google Patents

Ετεροκυκλικες ενωσεις

Info

Publication number
CY1116802T1
CY1116802T1 CY20151100774T CY151100774T CY1116802T1 CY 1116802 T1 CY1116802 T1 CY 1116802T1 CY 20151100774 T CY20151100774 T CY 20151100774T CY 151100774 T CY151100774 T CY 151100774T CY 1116802 T1 CY1116802 T1 CY 1116802T1
Authority
CY
Cyprus
Prior art keywords
heterocyclic compounds
relates
diseases
developmental
inflammatory
Prior art date
Application number
CY20151100774T
Other languages
Greek (el)
English (en)
Inventor
Chi-Feng Yen
Cheng-Kung Hu
Chang-Pin Huang
Ying-Huey Huang
Gholam Hossein Hakimelahi
Chi-Hsin Richard King
Original Assignee
Taigen Biotechnology Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taigen Biotechnology Co., Ltd. filed Critical Taigen Biotechnology Co., Ltd.
Publication of CY1116802T1 publication Critical patent/CY1116802T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY20151100774T 2008-04-21 2015-09-07 Ετεροκυκλικες ενωσεις CY1116802T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4649608P 2008-04-21 2008-04-21
EP08874003.0A EP2268635B1 (en) 2008-04-21 2008-11-03 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
CY1116802T1 true CY1116802T1 (el) 2017-03-15

Family

ID=41201620

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100774T CY1116802T1 (el) 2008-04-21 2015-09-07 Ετεροκυκλικες ενωσεις

Country Status (20)

Country Link
US (1) US8372849B2 (enExample)
EP (1) EP2268635B1 (enExample)
JP (1) JP5661607B2 (enExample)
KR (1) KR101579999B1 (enExample)
CN (1) CN101565404B (enExample)
AU (1) AU2008355098B2 (enExample)
CA (1) CA2720229C (enExample)
CY (1) CY1116802T1 (enExample)
DK (1) DK2268635T3 (enExample)
EA (1) EA019289B1 (enExample)
ES (1) ES2545731T3 (enExample)
HR (1) HRP20150932T2 (enExample)
HU (1) HUE025179T2 (enExample)
NZ (1) NZ588989A (enExample)
PL (1) PL2268635T3 (enExample)
PT (1) PT2268635E (enExample)
SI (1) SI2268635T1 (enExample)
TW (1) TWI444188B (enExample)
WO (1) WO2009131598A1 (enExample)
ZA (1) ZA201008262B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010056847A2 (en) * 2008-11-13 2010-05-20 Taigen Biotechnology Co., Ltd. Lyophilization formulation
CN103204816B (zh) * 2012-01-16 2016-04-27 中国人民解放军军事医学科学院毒物药物研究所 哌嗪基嘧啶类衍生物及其制备方法和用途
HK1206624A1 (en) * 2012-04-11 2016-01-15 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
CA2962329C (en) 2014-09-22 2023-12-19 Yu-Sheng Chao Heterocyclic compounds and use thereof
US9375406B2 (en) * 2014-09-30 2016-06-28 Taigen Biotechnology Co., Ltd. Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor
TWI620748B (zh) 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
AU2018208366B2 (en) * 2017-01-10 2020-12-17 National Health Research Institutes Heterocyclic compounds and use thereof
CN109553604B (zh) * 2017-09-25 2021-08-27 盛世泰科生物医药技术(苏州)有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
CN108794414B (zh) * 2018-06-22 2021-01-01 浙江大学 芳酰胺基取代的均三嗪类化合物及制备和应用
CN116120195B (zh) * 2022-12-29 2025-02-25 长兴宜生药物科技有限公司 一种催化制备培哚普利中间体的方法
PL247377B1 (pl) * 2023-06-29 2025-06-23 Politechnika Krakowska Im Tadeusza Kosciuszki Nowa pochodna 1,3,5-triazyny i jej zastosowanie

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6029A (en) * 1849-01-16 Method of directing the scoops in dredging machines
US3007A (en) * 1843-03-21 Improvement in salt-boilers
US5034560A (en) 1990-10-19 1991-07-23 The Standard Oil Company Synthesis of ethylamines
WO1993001498A1 (en) 1991-07-04 1993-01-21 Immunodex K/S Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
WO1997046250A1 (en) 1996-06-04 1997-12-11 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
JP2002514195A (ja) * 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
WO1999050249A2 (en) 1998-04-01 1999-10-07 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
AU759310B2 (en) 1998-08-20 2003-04-10 Agouron Pharmaceuticals, Inc. Non-peptide GnRH agents, methods and intermediates for their preparation
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
TW550258B (en) 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
CA2396693A1 (en) * 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
CA2465978C (en) * 2001-09-14 2015-04-07 Soon Hyung Woo Inhibitors of histone deacetylase
WO2003026665A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
US7544690B2 (en) 2001-10-01 2009-06-09 Taisho Pharmaceutical Co., Ltd. MCH receptor antagonists
ES2373226T3 (es) 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
EP1571146A4 (en) * 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
EP1590334B1 (en) 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
KR100806603B1 (ko) 2003-09-22 2008-02-29 에프. 호프만-라 로슈 아게 아미노알킬아미드 치환된 사이클로헥실 유도체
AU2005225471B2 (en) * 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
NZ552298A (en) 2004-05-23 2011-04-29 Gerard M Housey Method for identifying inhibitors or activators of a theramutein by comparing the phenoresponse of cells exposed to a test compound
JP2006124387A (ja) * 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
WO2007037898A2 (en) 2005-08-29 2007-04-05 Housey Pharmaceuticals Inc Theramutein modulators
EA015890B1 (ru) 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Производные пиримидина
BRPI0616575A2 (pt) 2005-09-27 2011-06-21 Irm Llc compostos e composições contendo diarilamina, seu uso como moduladores de receptores de c-kit bem como método para sua produção
EP4424838A3 (en) 2005-11-23 2024-12-04 Gerard M. Housey Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
CN101563336A (zh) 2006-03-16 2009-10-21 诺瓦提斯公司 用于治疗特别是黑素瘤的杂环有机化合物
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
AU2007269540B2 (en) * 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators

Also Published As

Publication number Publication date
ZA201008262B (en) 2011-07-27
HK1138269A1 (en) 2010-08-20
KR20110008085A (ko) 2011-01-25
EP2268635A1 (en) 2011-01-05
PT2268635E (pt) 2015-10-06
CN101565404A (zh) 2009-10-28
EA201071221A1 (ru) 2011-08-30
CA2720229A1 (en) 2009-10-29
NZ588989A (en) 2012-03-30
JP5661607B2 (ja) 2015-01-28
EP2268635B1 (en) 2015-06-10
US8372849B2 (en) 2013-02-12
DK2268635T3 (en) 2015-09-14
PL2268635T3 (pl) 2015-11-30
SI2268635T1 (sl) 2015-10-30
CN101565404B (zh) 2012-12-05
WO2009131598A1 (en) 2009-10-29
ES2545731T3 (es) 2015-09-15
AU2008355098B2 (en) 2012-11-15
HRP20150932T1 (xx) 2015-10-09
HRP20150932T2 (hr) 2017-10-20
KR101579999B1 (ko) 2015-12-23
JP2011519360A (ja) 2011-07-07
EA019289B1 (ru) 2014-02-28
CA2720229C (en) 2015-02-17
AU2008355098A1 (en) 2009-10-29
TW200944206A (en) 2009-11-01
TWI444188B (zh) 2014-07-11
US20090264339A1 (en) 2009-10-22
EP2268635A4 (en) 2012-02-22
HUE025179T2 (en) 2016-02-29

Similar Documents

Publication Publication Date Title
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1125436T1 (el) Αναστολεις dna-pk
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
CY1123470T1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
CY1119399T1 (el) Aντι-dkk-1 αντισωματα
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CY1121299T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CY1120665T1 (el) Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
CY1118157T1 (el) Εκλεκτικοι αναστολεις γλυκοσιδασης και χρησεις αυτων
EA201171367A1 (ru) Винилиндазолильные соединения
CY1119751T1 (el) Υλικα και μεθοδοι για θεραπεια ή προληψη ασθενειων που σχετιζονται me her-3
CY1118156T1 (el) Ενωσεις αντιστροφης αμιδης ως αναστολεις δεακετυλασης πρωτεϊνων και μεθοδοι χρησης αυτων
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
CY1113485T1 (el) Ενωσεις γεφυρωμενης-πιπεριδινης τυπου υποκατεστημενης-κινοξαλινης και οι χρησεις εξ' αυτων
EA201270535A1 (ru) Пуриновые производные, применимые в качестве ингибиторов hsp90
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA201001639A1 (ru) Композиции и способы их получения и применения
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201170832A1 (ru) Пуриновые соединения
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201071221A1 (ru) Гетероциклические соединения